Color MPI as a novel method for in vivo assessment of magnetic nanoparticle dynamics and binding

Information

  • Research Project
  • 10249102
  • ApplicationId
    10249102
  • Core Project Number
    R44EB029877
  • Full Project Number
    5R44EB029877-02
  • Serial Number
    029877
  • FOA Number
    PA-19-272
  • Sub Project Id
  • Project Start Date
    9/1/2020 - 3 years ago
  • Project End Date
    8/31/2022 - a year ago
  • Program Officer Name
    WANG, SHUMIN
  • Budget Start Date
    9/1/2021 - 2 years ago
  • Budget End Date
    8/31/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
  • Award Notice Date
    8/16/2021 - 2 years ago
Organizations

Color MPI as a novel method for in vivo assessment of magnetic nanoparticle dynamics and binding

Summary: Current biomedical imaging methods are indispensable for diagnosing high-mortality diseases like Cancer, Cardiovascular Disease and Stroke. For decades, researchers have attempted to improve the contrast of these imaging methods by injecting two-component ?molecular imaging tracers?: an invisible, physiologically specific targeting agent (peptide, antibody, etc) attached to a visible reporter. Here we propose a new imaging method, called Color MPI, that improves the contrast of molecular imaging by seeing only those tracers that bind specifically to a diseased tissue. As one example, a scientist could discover an antibody that binds specifically to sites of vascular inflammation and create a targeting agent. This antibody can be attached to a magnetic nanoparticle reporter (a superparamagnetic iron oxide SPIO) and the combined tracer can highlight atherosclerotic plaques in a T2*-weighted MRI. Similarly, Her2-positive breast cancer may be revealed by targeted antibodies attached to nuclear medicine reporters (e.g., 111-In, 99mTc). ?A stubborn challenge that reduces the sensitivity and specificity of these methods is that unbound reporters greatly outnumber bound reporters, often by 100-fold, effectively obscuring the pathophysiology. It would be a major advance in medical molecular imaging if bound and unbound reporters could be separated in the image, as contrast would improve dramatically. However, current imaging modalities cannot distinguish bound from unbound tracers. In our prior work we have developed a revolutionary, noninvasive, and exquisitely sensitive imaging method called Magnetic Particle Imaging (MPI), which shows outstanding promise for biomedical imaging. Moreover, the unique physics of MPI allows one to distinguish bound from unbound magnetic nanoparticles, although this technology is still in its infancy and requires improvements to its robustness for successful commercialization. In this grant, we propose to develop Color MPI (c-MPI) into our commercial pre-clinical imager and enable scientists and clinicians to unmix particles in bound and unbound states.

IC Name
NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING
  • Activity
    R44
  • Administering IC
    EB
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    802387
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    286
  • Ed Inst. Type
  • Funding ICs
    NIBIB:802387\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MAGNETIC INSIGHT, INC.
  • Organization Department
  • Organization DUNS
    078791637
  • Organization City
    Alameda
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    945011098
  • Organization District
    UNITED STATES